Trialbee and Castor Partner to Democratize Access and Simplify Enrollment to Clinical Trials Globally
21.9.2021 14:58:00 EEST | Business Wire | Press release
Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005005/en/
Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs.
“We are excited to partner with Trialbee to improve patient engagement, as well as optimize patient diversity and study inclusivity with real-time insights around patient demographics across all recruitment channels,” said Derk Arts, M.D., Ph.D., CEO & Founder, Castor. “Our partnership provides sponsors a seamless decentralized and hybrid clinical trial solution to manage all their clinical trial touchpoints and expand inclusivity at a global scale.”
Recruiting and retaining qualified clinical trial participants is increasingly difficult as clinical study designs become more complex. According to industry estimates, the amount of patient eligibility in clinical trials has increased approximately 150% in the last decade. As a result, life sciences companies demand a patient matching and enrollment platform that can help them better manage the patient’s journey into a clinical trial while optimizing enrollment outcomes. With Trialbee and Castor’s proven integrations, clinical trial sponsors can seamlessly manage all clinical trial touchpoints while ensuring data quality every step of the way.
“Over 70 percent of potential clinical trial participants live more than two hours away from a trial site, increasing the need for greater scale and reach in patient awareness for today’s trial designs,” said Matt Walz, Chief Executive Officer at Trialbee. “Through our combined capabilities, clinical trials can deploy an end-to-end solution to simplify the patient journey, including early introductions to clinical trials, enrollment performance analytics, and remote data capture for decentralized clinical trials.”
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our enrollment platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs, and virtual/decentralized sites, and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.
About Castor
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005005/en/
Contact information
Doug Weatherhead
Castor
doug.weatherhead@castoredc.com
Media
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 15:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duration while maintaining flexible, up to once-monthly dosing for patients (every three or four weeks for PID). The TAK-881-3001 clinical trial ev
Ouster Releases The REV8 OS Family: The World’s First Native Color Lidar4.5.2026 13:00:00 EEST | Press release
Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, announced today its new family of OS digital lidar sensors, Rev8, powered by its next-generation L4 Ouster Silicon. Ouster Rev8 features the world’s first patented native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504718668/en/ The REV8 OS Family: The World's First Native Color Lidar. L4 Ouster Silicon: Ouster’s breakthrough L4 architecture doubles the range and resolution of its lidar over the prior generation, adds native-color sensing, and is designed for functional safety. Based on patented Ouster Silicon with embedded Fujifilm color science, the L4 chip results in exquisite color data and hardware-enabled HDR. It boasts 42.9 GMACs of p
NIQ Research Reveals New Rules of Commerce: AI Is Beginning to Decide What Consumers Buy4.5.2026 13:00:00 EEST | Press release
NielsenIQ (NYSE: NIQ) has announced the release of its new global report, The Commerce Revolution: Where East Meets West, which examines how Eastern-led commerce innovation and Western retail media monetization are colliding to reshape global consumer commerce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428841965/en/ The report finds live, social, and quick commerce—long scaled across Asia—now drive most incremental digital growth worldwide, while Western markets accelerate adoption as these formats localize. At the same time, retail media networks (RMNs) have become one of the fastest‑growing advertising channels globally, with US retail media ad spend projected to reach $107.6 billion (USD) in 2026. Beyond this, the report finds that previously siloed operational functions of sellers are beginning to blur boundaries. Payment platforms and rapid fulfillment models from the East are converging with the monetization mo
OPAQUE Acquires Abu Dhabi-Developed Cryptographic AI Technology from TII, Extending Confidential AI Across the Full Lifecycle with Post-Quantum Protection4.5.2026 11:23:00 EEST | Press release
OPAQUE, the Confidential AI company headquartered in San Francisco, California, today announced it has acquired advanced cryptographic AI technologies from the Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi's Advanced Technology Research Council (ATRC). The acquired technology — already proven in real-world use cases — adds two critical capabilities to OPAQUE's platform: confidential AI model training powered by advanced cryptographic techniques such as multi-party computation and fully homomorphic encryption, as well as post-quantum cryptographic protections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504705475/en/ OPAQUE Acquires Abu Dhabi-Developed Cryptographic AI Technology from TII, Extending Confidential AI Across the Full Lifecycle with Post-Quantum Protection (Photo: AETOSWire) Founded by researchers from UC Berkeley's RISELab, and now with this acquisition, OPAQUE supports Co
Forbes Includes Philip Morris International in Its Net Zero Leaders List4.5.2026 11:00:00 EEST | Press release
Philip Morris International (PMI) (NYSE: PM) has been included once more in Forbes’ 2026 Net Zero Leaders1 list, recognizing its leadership and continued progress in advancing climate action across its global operations. The Forbes Net Zero Leaders list highlights U.S. publicly listed companies best positioned to achieve net zero emissions by 2050, based on measurable performance rather than commitments alone. Despite most companies aligning to a 2050 net zero horizon, PMI remains committed to reaching net zero by 2040, as set out in its Climate Transition Plan published in 2025. This aspiration reflects PMI’s confidence in collective progress, trust that ambition drives innovation, that policy will evolve to enable change, and collaboration will accelerate system‑wide transformation. Above all, it signals hope: that by acting early and holding firm, PMI can help build the critical momentum needed to shift markets, technologies, and mindsets, and inspire similar action across its value
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom